p53-deficient cancer cells (p53)

“p53-deficient cancer cells” refers to cancerous cell populations that lack functional tumor protein p53, most commonly due to mutations in the TP53 gene. Tumor protein p53 is a critical transcription factor known as “the guardian of the genome,” responsible for regulating cell cycle arrest, DNA repair, and apoptosis following cellular stress or DNA damage. Loss or mutation of this gene disables these protective mechanisms, allowing damaged cells to proliferate unchecked—a hallmark event in many human cancers. More than half of all human tumors harbor mutations that disrupt normal function or expression levels of this key tumor suppressor.[1][3][5] While there are no approved therapies that directly target “p53 deficiency,” ongoing research focuses on restoring its activity pharmacologically or exploiting synthetic lethal interactions unique to these vulnerable cancer cell populations.[4]

Other names

TP53-deficient cancer cellsCancer cells lacking functional p53Cells with TP53 mutation

Restoration/reactivation of mutant or suppressed wild-type p53 activity - Induction of apoptosis in absence of functional checkpoint control - Synthetic lethality approaches exploiting vulnerabilities unique to these deficient backgrounds